|
Post by dreamboatcruise on Oct 17, 2016 16:32:51 GMT -5
In three weeks. Management should be more free to talk about Sanofi settlements. Perhaps news of RLS milestone. Management needs to tell us they have cash and the plan for the label/pediatric trial. Or what the hell the plan is.
The worlds dream fast acting insulin. Can you believe it?
Peppy If you are asking how it is possible that a company with such a great technology could be faced with such an improbable financial situation, I can only reply that this year, the improbable seems to rule. Somehow, Lewis Carroll got control of the world's rudder to steer us through the looking glass into a place where ordinary language is inadequate to describe what we are now experiencing. So our only practical option is to enjoy the ride in wonderment, turning to each other in amazement while repeating the question "really?". GLTAL Chris C "The time has come," the Walrus said, "To talk of many things: Of Sales, and scripts, and settlements... Of cabbages, and kings-- And why the stock is selling not, And whether we have wings."
|
|
|
Post by derek2 on Oct 17, 2016 17:16:05 GMT -5
|
|
|
Post by tayl5 on Oct 17, 2016 22:58:48 GMT -5
For those who seem confused, a reverse split does not raise any money, it just solves the threat of delisting because the stock price is too low. If the r/s is accompanied by a financing event, it will likely also involve dilution. Dilution is not fun, but better than extinction.
|
|
|
Post by agedhippie on Oct 18, 2016 9:41:35 GMT -5
For those who seem confused, a reverse split does not raise any money, it just solves the threat of delisting because the stock price is too low. If the r/s is accompanied by a financing event, it will likely also involve dilution. Dilution is not fun, but better than extinction. Tell me about it! I hold CORR which did a 5:1 reverse split back in December and immediately dropped 50%. It had recovered 6 months later but it wasn't a pleasant experience.
|
|
|
Post by mnkdfann on Oct 18, 2016 23:16:34 GMT -5
Some conference call expectations on the street: postregistrar.com/2016/10/18/noticeable-stock-mannkind-corporation-nasdaqmnkd/The consensus mean EPS for the current quarter is at $-0.05 derived from a total of 3 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.06 and can go high up to $-0.05. However a year ago during same quarter MannKind Corporation (NASDAQ:MNKD) reported $-0.08 EPS. For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.06 per share according to consensus of 3 analysts. According to sentiments of 4 analysts the company is expected to report revenues of $1M for the current quarter. Bullish revenue forecast has been figured out at $2M. According to sentiments of 2 analysts the mean estimates of short term price target for the company’s stock is marked at $0.15. The most optimistic analyst sees the stock reaching $0.20 while the most conventional predicts the target price at $0.10.
|
|
|
Post by prvs on Oct 19, 2016 7:09:27 GMT -5
Some conference call expectations on the street: postregistrar.com/2016/10/18/noticeable-stock-mannkind-corporation-nasdaqmnkd/The consensus mean EPS for the current quarter is at $-0.05 derived from a total of 3 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.06 and can go high up to $-0.05. However a year ago during same quarter MannKind Corporation (NASDAQ:MNKD) reported $-0.08 EPS. For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.06 per share according to consensus of 3 analysts. According to sentiments of 4 analysts the company is expected to report revenues of $1M for the current quarter. Bullish revenue forecast has been figured out at $2M. According to sentiments of 2 analysts the mean estimates of short term price target for the company’s stock is marked at $0.15. The most optimistic analyst sees the stock reaching $0.20 while the most conventional predicts the target price at $0.10. Remember when we all boo'ed and hissed at the GS analyst who gave MNKD a 10 cent price target?
|
|
|
Post by dictatorsaurus on Oct 19, 2016 7:24:43 GMT -5
Shorts, AF and the analysts were all mocked. I guess the joke is on us?
Mike C. is getting hammered pretty hard on social media. That wasn't the case before. People are angry and restless and demanding answers. The response from management is silence. I don't think they are hiding any lucrative secret plan. I truly believe they have nothing to share.
|
|
|
Post by peppy on Oct 19, 2016 7:33:21 GMT -5
Management has to have something. The plan was to hire a sales team and market afrezza.
|
|
|
Post by agedhippie on Oct 19, 2016 7:57:48 GMT -5
Shorts, AF and the analysts were all mocked. I guess the joke is on us? Mike C. is getting hammered pretty hard on social media. That wasn't the case before. People are angry and restless and demanding answers. The response from management is silence. I don't think they are hiding any lucrative secret plan. I truly believe they have nothing to share. If there is nothing to say then it is better to remain silent rather than remove any doubt. Years ago I worked for a company that over-communicated and it was very lucrative - every time management had a conference call the share price dropped because there was no news, and aided no doubt by half the employees promptly shorting the stock on announcement of the CC.
|
|
|
Post by sayhey24 on Oct 19, 2016 19:54:16 GMT -5
I am OK with no news as long as these guys are getting it done. The problem right now is its November. The honeymoon for Mike is over but he too is about $100k in the hole so that brings hope. Are they getting the deals done? Who knows but Matt and Mike but that's all I care about. For example - Whats going on with Dexcom? Kevin Sayer said his best salesman for his CGM's is afrezza. Dexcom has to be doing something with Onduo since they are funding Verily's CGM development effort. How about Vdex? Are they selling afrezza direct and if so how do we get 1000 offices open. Is there a connection between Onduo and Vdex, is Vdex using the Onduo backend system they are testing with Sutter and Allegheny and whats Steve Edelman doing with MNKD. We know he is doing something with Onduo. How about the international deals and the $200M sale to that little country. How about China and San Meditech. They already have am Onduo like cloud system. Whats going on with Sanofi, are they in or out and if they are really out why has a law suit not been issued. I could ramble on and on but it all come down to getting it done and now. The pps at this point really can't go much lower. It sure can't drop $1 let alone the $10 it already has.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 19, 2016 20:22:19 GMT -5
^^ you need your own sub forum for " my fantasies" beware you are worse than the Debbie downers I have seen here ... two extremes
|
|